A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide. The trial, led by Keith McCrae, M.D., of Cleveland Clinic and supported by the National Institutes of Health, was stopped early because of these successful findings, and has been published in the New England Journal of Medicine.
Medicaid & Health Equity: Disparities in Maternal and Mental Health
Kim Webb, VP of Health Strategy at Siftwell Analytics Recent advancements in healthcare, such as telemedicine, automation, and clinical studies, have propelled the industry forward,
November 12, 2024